



King's Research Portal

DOI:

[10.3233/JAD-170231](https://doi.org/10.3233/JAD-170231)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Fladby, T., Palhaugen, L., Selnes, P., Waterloo, K., Brathen, G., Hessen, E., Almdahl, I. S., Arntzen, K-A., Auning, E., Eliassen, C. F., Espenes, R., Grambaite, R., Grontvedt, G. R., Johansen, K. K., Johnsen, S. H., Kalheim, L. F., Kirsebom, B-E., Muller, K. I., Nakling, A. E., ... Aarsland, D. (2017). Detecting At-Risk Alzheimer's Disease Cases. *JOURNAL OF ALZHEIMERS DISEASE*, 60(1), 97-105. <https://doi.org/10.3233/JAD-170231>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Detecting At-Risk Alzheimer's Disease Cases

Tormod Fladby^{a,b}, Lene Pålhaugen^{a,b,*}, Per Selnes^{a,b}, Knut Waterloo^{c,d}, Geir Bråthen^{e,f}, Erik Hessen^{a,g}, Ina Selseth Almdahl^{a,b}, Kjell-Arne Arntzen^{c,h}, Eirik Auningⁱ, Carl Fredrik Eliassen^{a,g}, Ragna Espenes^{c,d}, Ramune Grambaite^a, Gøril Rolfseng Grøntvedt^{e,f}, Krisztina Kunszt Johansen^a, Stein Harald Johnsen^{c,h}, Lisa Flem Kalheim^{a,b}, Bjørn-Eivind Kirsebom^{c,d}, Kai Ivar Müller^{j,k}, Arne Exner Nakling^{l,m}, Arvid Rongve^{n,o}, Sigrid Botne Sando^{e,f}, Nikias Siafarikasⁱ, Ane Løvli Stav^{a,b}, Sandra Tecelao^p, Santiago Timon^a, Svein Ivar Bekkelund^{j,k} and Dag Aarsland^{a,m,q}

^aDepartment of Neurology, Akershus University Hospital, Lørenskog, Norway

^bInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway

^cDepartment of Neurology, University Hospital of North Norway, Tromsø, Norway

^dDepartment of Psychology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway

^eDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

^fDepartment of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway

^gDepartment of Psychology, University of Oslo, Oslo, Norway

^hDepartment of Clinical Medicine, Brain and Circulation Research Group, UiT The Arctic University of Norway, Tromsø, Norway

ⁱDepartment of Geriatric Psychiatry, Akershus University Hospital, Lørenskog, Norway

^jDepartment of Neurology and National Neuromuscular Centre, University Hospital of North Norway, Tromsø, Norway

^kDepartment of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway

^lInstitute of Clinical Medicine, University of Bergen, Bergen, Norway

^mCentre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway

ⁿDepartment of Research and Innovation, Haugesund Hospital, Helse Fonna, Haugesund, Norway

^oDepartment of Clinical Medicine, The University of Bergen, Bergen, Norway

^pThe Intervention Centre, Oslo University Hospital, Oslo, Norway

^qDepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

Accepted 22 June 2017

Abstract. While *APOE* $\epsilon 4$ is the major genetic risk factor for Alzheimer's disease (AD), amyloid dysmetabolism is an initial or early event predicting clinical disease and is an important focus for secondary intervention trials. To improve identification of cases with increased AD risk, we evaluated recruitment procedures using pathological CSF concentrations of $A\beta_{42}$ (pA β) and *APOE* $\epsilon 4$ as risk markers in a multi-center study in Norway. In total, 490 subjects aged 40–80 y were included after response to advertisements and media coverage or memory clinics referrals. Controls ($n = 164$) were classified as normal controls without first-degree relatives with dementia (NC), normal controls with first-degree relatives with dementia (NCFD), or controls scoring below norms on cognitive screening. Patients ($n = 301$) were classified as subjective cognitive decline or

*Correspondence to: Lene Pålhaugen, P.B. 1000, N-1478 Lørenskog, Norway. Tel.: +47 95832775; E-mail: lene.palhaugen@gmail.com.

mild cognitive impairment. Subjects underwent a clinical and cognitive examination and MRI according to standardized protocols. Core biomarkers in CSF from 411 and *APOE* genotype from 445 subjects were obtained. Cases (both self-referrals ($n = 180$) and memory clinics referrals ($n = 87$)) had increased fractions of pA β and *APOE* $\epsilon 4$ frequency compared to NC. Also, NCFD had higher *APOE* $\epsilon 4$ frequencies without increased fraction of pA β compared to NC, and cases recruited from memory clinics had higher fractions of pA β and *APOE* $\epsilon 4$ frequency than self-referred. This study shows that memory clinic referrals are pA β enriched, whereas self-referred and NCFD cases more frequently are pA β negative but at risk (*APOE* $\epsilon 4$ positive), suitable for primary intervention.

Keywords: Alzheimer's disease, amyloid, apolipoprotein E4, biomarkers, cerebrospinal fluid, mild cognitive impairment, subjective cognitive decline

INTRODUCTION

Alzheimer's disease (AD) is the major cause of memory loss and dementia and a main cause for increasing costs for health care and death. Several strategies for AD treatment are being pursued, and early diagnostics and intervention will be necessary. AD has been shown to encompass long pre-clinical and pre-dementia periods, but among those seeking help at memory clinics for early cognitive symptoms, non-AD causes (e.g. stress, worrying, and depression) are predominant [1–3]. Though memory symptoms are a major cause for concern among the elderly, few seek medical help for these symptoms [4]. Better characterization of target groups and more accurate and efficient screening procedures for early AD disease activity are crucial to recruit people with incipient AD and early stage disease for clinical trials.

A long AD pre-dementia period encompassing amyloid- β protein precursor dysmetabolism, amyloid plaque formation and inflammation has been described, initially without subjective cognitive dysfunction, then in some individuals with subjective cognitive decline (SCD) and ultimately with mild cognitive impairment (MCI) [2, 5–7]. Several definitions of AD manifestations in this period have been developed. Two pre-clinical AD stages, (1) asymptomatic amyloidosis and (2) asymptomatic amyloidosis + neurodegeneration have been suggested as precursors for SCD and MCI [3]. PET amyloid imaging and cerebrospinal fluid (CSF) amyloid- β (A β)₄₂ measurements are considered as equivalent biomarkers for brain amyloid deposition, though the CSF measure of low CSF A β ₄₂ (pA β) has been reported to give an earlier signal [8]. Subtle loss of grey and white matter integrity is closely coupled to cognitive impairment in the pre-dementia AD stage [9, 10]. The apolipoprotein E (*APOE*) $\epsilon 4$ allele is a well-established genetic risk factor for AD, and several polymorphisms associated with AD have been related to A β metabolism [11–16]. The exact

mechanisms causing early neurodegeneration remain to be established, but most current treatment trials focus on altering amyloid metabolism at the MCI stage [17, 18].

The brain has extensive compensatory mechanisms for gradually acquired neuronal damage. Realizing that not only dementia, but also MCI appears late in the AD disease process, the prevalence of AD-like pathology among cognitively normal cases has attracted increased interest and some data has been published [19, 20].

We aimed to identify subjects suitable for primary AD intervention studies, and therefore investigated whether recruitment strategies focusing on self-referred cases with cognitive symptoms and ordinary referrals to memory clinics identified cases with pA β and at-risk subjects without AD pathology differently.

METHODS

As part of “Dementia Disease Initiation” (DDI), a co-operation between all Norwegian health regions and university hospitals, subjects with self-reported cognitive reduction and healthy controls were recruited from January 2013 till January 2017 and examined following a standard protocol. Anonymized data were collected in a customized database. Recruitment was based on two main sources: 1) Cases were self-referred following advertisements in media, newspapers or news bulletins, or 2) recruited among referrals to local memory clinics. In addition, cognitively healthy controls were also included from spouses of patients with dementia/cognitive disorder, and from patients who completed lumbar puncture for orthopedic surgery. Participants were staged as controls, SCD or MCI using published criteria based on the comprehensive assessment program (see below) [5, 21]. The controls were further classified as having normal or abnormal cognitive screening and with or without first-degree

relative with dementia. Criteria for inclusion were age between 40 and 80 and a native language of Norwegian, Swedish, or Danish. Exclusion criteria were brain trauma or disorder, including clinical stroke, dementia, severe psychiatric disease, severe somatic disease that might influence the cognitive functions, or intellectual disability or other developmental disorders.

A case report form was developed which included medical history from subject and informant, and physical and neurological examinations including cognitive examination and the 15-item Geriatric Depression Score (GDS) [22]. Educational levels were operationalized according to normative classification [23]; 0=Primary school (7–8 y), 1=High School (9–11 y), 2=College (12 y), 3=Bachelor degree (13–15 y), 4=Master or equivalent (16–17 y), 5=Higher university degree/PhD (18–20 y). The cognitive examination included the Mini Mental State Examination (MMSE-NR) [24], non-verbal cognitive screening (the clock drawing test) [25], verbal memory (CERAD word list) [26], visuoperceptual ability (VOSP silhouettes), psychomotor speed and divided attention (Trail making A and B and word fluency (COWAT) [27].

All subjects gave their written consent, and the Regional Committee for Medical and Health Research Ethics South-East evaluated (based on the Norwegian Health and Research Act and the Helsinki Declaration of 1964; revised 2013) and approved the study. All further study conduct was in line with these guidelines.

Cognitive staging

Symptomatic subjects with normal performance on standardized tests were classified as SCD, as defined in the framework by the working group of SCD [5]. The NIA-AA criteria for MCI were used for cases with lower performance than expected in one or more cognitive domains, but yet preserved independence in functional ability and not fulfilling the criteria of dementia, as defined in NIA-AA guidelines [21, 28]. Performance was classified as normal or abnormal according to published norms for the different tests [24–27, 29–31]. The cutoff values for SCD versus MCI (defined as normal or abnormal cognition) were results equal to or 1.5 standard deviation below normative mean on either CERAD word list (delayed recall), VOSP silhouettes, TMT-B or COWAT, or having MMSE score equal to or below 27. Cognitive functioning was also assessed

by the Clinical Dementia Rating scale (CDR) [32]. Cases with dementia were excluded if CDR was >0.5 [33].

Biomarkers

Lumbar puncture was performed before noon, and CSF was collected in polypropylene tubes (Thermo Nunc) and centrifuged within 4 h at 2000 g for 10 min at room temperature. The supernatant was transferred to new tubes and frozen at -80°C prior to analysis. All CSF samples were analyzed at the Department of Interdisciplinary Laboratory Medicine and Medical Biochemistry at Akershus University Hospital, and samples from other sites were frozen before sending to this laboratory. CSF $\text{A}\beta_{42}$, total tau, and phosphorylated tau were determined using ELISA (Innotest β -Amyloid (1–42), Innotest h-Tau Ag and Innotest Phospho-Tau (181P), Fujirebio, Ghent, Belgium).

APOE genotyping was performed on EDTA blood samples either at Akershus University Hospital (Gene Technology Division, Department of Interdisciplinary Laboratory Medicine and Medical Biochemistry) according to the laboratory's routine protocol using real-time PCR combined with a TaqMan assay (Applied Biosystems, Thermo Fisher Scientific, Waltham, USA) or at the University Hospital of Trondheim according to the protocol for the Fast Start DNA Master HybProbe Kit (Roche, Basel, Switzerland) in combination with the LightMix ApoE C112R R158C kit from TiB MolBiol (Berlin, Germany) followed by LightCycler technology (Roche, Basel, Switzerland).

All subjects were referred to an MRI scan, and if available also to FDG-PET and amyloid PET.

Data analysis

The subjects with cognitive symptoms were categorized both by stage (Table 1) and by recruitment method (Table 2). The derived variable "*APOE* $\epsilon 4$ positive" was defined as having at least one *APOE* $\epsilon 4$ allele. The CSF $\text{A}\beta_{42}$ measurements were dichotomized using a threshold of 708 ng/L, with values below the threshold defined as positive. This current CSF $\text{A}\beta_{42}$ threshold for research use was determined based on best fit to flutemetamol PET results (based on 42 subjects for whom CSF and flutemetamol PET was available, of whom 16 subjects was flutemetamol PET positive and 26 subjects was flutemetamol PET negative), as described in [34]

Table 1

Demographic characteristics, cognitive test results, *APOE* alleles and CSF A β pathology of the control and symptomatic subjects classified by cognitive stage

	Total	Control subjects			Subjects with cognitive symptoms	
		Without family History	With family history	Abnormal cognitive Screening	SCD	MCI
Age at inclusion (SD)	62.9 (9.4) <i>n</i> = 463	63.2 (9.6) <i>n</i> = 46	58.9 (8.9) <i>n</i> = 86 <i>p</i> < 0.05 ^a	65.2 (7.6) <i>n</i> = 32 <i>p</i> = n.s. ^a	62.3 (8.9) <i>n</i> = 163 <i>p</i> = n.s. ^a	65.4 (9.8) <i>n</i> = 136 <i>p</i> = n.s. ^a
Female/Total	253/465 54.4%	22/46 47.8%	53/86 61.6% <i>p</i> = n.s. ^c	21/32 65.6% <i>p</i> = n.s. ^c	93/164 56.7% <i>p</i> = n.s. ^c	64/137 46.7% <i>p</i> = n.s. ^c
Education level (IQR)	3.0 (1.0) <i>n</i> = 461	3.0 (2.0) <i>n</i> = 46	3.0 (2.0) <i>n</i> = 85 <i>p</i> = 0.05 ^b	2.0 (2.0) <i>n</i> = 31 <i>p</i> = n.s. ^b	3.0 (3.0) <i>n</i> = 163 <i>p</i> = n.s. ^b	3.0 (2.0) <i>n</i> = 136 <i>p</i> = n.s. ^b
MMSE (IQR)	29.0 (2.0) <i>n</i> = 461	29.0 (1.0) <i>n</i> = 45	30.0 (1.0) <i>n</i> = 86 <i>p</i> = n.s. ^b	28.0 (2.0) <i>n</i> = 32 <i>p</i> < 0.001 ^b	29.0 (1.0) <i>n</i> = 163 <i>p</i> = n.s. ^b	28.0 (3.0) <i>n</i> = 135 <i>p</i> < 0.001 ^b
CERAD word list recall T-score (SD)	48.9 (14.0) <i>n</i> = 453	50.1 (13.6) <i>n</i> = 45	57.9 (8.7) <i>n</i> = 85 <i>p</i> < 0.01 ^a	48.3 (11.5) <i>n</i> = 32 <i>p</i> = n.s. ^a	53.1 (10.3) <i>n</i> = 161 <i>p</i> = n.s. ^a	37.5 (14.4) <i>n</i> = 130 <i>p</i> < 0.001 ^a
VOSP silhouettes T-score (SD)	49.2 (11.1) <i>n</i> = 419	50.6 (8.0) <i>n</i> = 38	53.8 (9.2) <i>n</i> = 82 <i>p</i> = n.s. ^a	43.1 (13.6) <i>n</i> = 29 <i>p</i> < 0.05 ^a	52.3 (9.8) <i>n</i> = 143 <i>p</i> = n.s. ^a	43.6 (10.9) <i>n</i> = 127 <i>p</i> < 0.001 ^a
TMT-B T-score (SD)	47.5 (10.2) <i>n</i> = 443	53.7 (8.3) <i>n</i> = 43	50.5 (8.9) <i>n</i> = 84 <i>p</i> = n.s. ^a	44.2 (7.9) <i>n</i> = 32 <i>p</i> < 0.001 ^a	49.6 (8.7) <i>n</i> = 161 <i>p</i> < 0.05 ^a	41.3 (11.0) <i>n</i> = 123 <i>p</i> < 0.001 ^a
COWAT T-score (SD)	48.9 (9.8) <i>n</i> = 452	51.1 (6.8) <i>n</i> = 44	50.2 (8.1) <i>n</i> = 84 <i>p</i> = n.s. ^a	43.7 (10.1) <i>n</i> = 32 <i>p</i> < 0.01 ^a	51.5 (9.9) <i>n</i> = 160 <i>p</i> = n.s. ^a	45.6 (10.1) <i>n</i> = 132 <i>p</i> < 0.001 ^a
GDS score (IQR)	1.0 (3.0) <i>n</i> = 448	0.0 (1.0) <i>n</i> = 45	0.0 (1.0) <i>n</i> = 81 <i>p</i> = n.s. ^b	0.5 (1.0) <i>n</i> = 32 <i>p</i> = n.s. ^b	2.0 (3.0) <i>n</i> = 156 <i>p</i> < 0.001 ^b	3.0 (3.0) <i>n</i> = 134 <i>p</i> < 0.001 ^b
<i>APOE</i> ϵ 4 positivity	196/430 45.6%	9/43 20.9%	45/82 54.9% <i>p</i> < 0.001 ^c	12/32 37.5% <i>p</i> = n.s. ^c	64/147 43.5% <i>p</i> < 0.01 ^c	66/126 52.4% <i>p</i> < 0.001 ^c
<i>APOE</i> ϵ 4 allele frequency	25.7%	10.5%	28.7% <i>p</i> < 0.01 ^c	20.3% <i>p</i> = n.s. ^c	24.8% <i>p</i> < 0.01 ^c	31.3% <i>p</i> < 0.001 ^c
<i>APOE</i> ϵ 2/ ϵ 2	<i>n</i> = 430 0 (0.0%)	<i>n</i> = 43 0 (0.0%)	<i>n</i> = 82 0 (0.0%)	<i>n</i> = 32 0 (0.0%)	<i>n</i> = 147 0 (0.0%)	<i>n</i> = 126 0 (0.0%)
ϵ 2/ ϵ 3	35 (8.1%)	7 (16.3%)	2 (2.4%) <i>p</i> < 0.01 ^d	6 (18.8%) <i>p</i> = n.s. ^c	14 (9.5%) <i>p</i> = n.s. ^d	6 (4.8%) <i>p</i> < 0.05 ^d
ϵ 3/ ϵ 3	199 (46.3%)	27 (62.8%)	35 (42.7%) <i>p</i> < 0.05 ^c	14 (43.8%) <i>p</i> = n.s. ^c	69 (46.9%) <i>p</i> = n.s. ^c	54 (42.9%) <i>p</i> < 0.05 ^c
ϵ 2/ ϵ 4	15 (3.5%)	1 (2.3%)	6 (7.3%) <i>p</i> = n.s. ^d	1 (3.1%) <i>p</i> = n.s. ^d	3 (2.0%) <i>p</i> = n.s. ^d	4 (3.2%) <i>p</i> = n.s. ^d
ϵ 3/ ϵ 4	156 (36.3%)	8 (18.6%)	37 (45.1%) <i>p</i> < 0.01 ^c	10 (31.3%) <i>p</i> = n.s. ^c	52 (35.4%) <i>p</i> < 0.05 ^c	49 (38.9%) <i>p</i> < 0.05 ^c
ϵ 4/ ϵ 4	25 (5.8%)	0 (0.0%)	2 (2.4%) <i>p</i> = n.s. ^d	1 (3.1%) <i>p</i> = n.s. ^d	9 (6.1%) <i>p</i> = n.s. ^d	13 (10.3%) <i>p</i> < 0.05 ^d
CSF A β ₄₂ positivity	89/393 22.7%	2/39 5.1%	4/62 6.5% <i>p</i> = n.s. ^d	6/25 24.0% <i>p</i> < 0.05 ^d	24/145 16.6% <i>p</i> = n.s. ^c	53/122 43.4% <i>p</i> < 0.001 ^c

Continuous variables of assumed normal distribution (*age at inclusion*, *CERAD word list recall T-score*, *VOSP silhouettes T-score*, *TMT-B T-score*, and *COWAT T-score*) are summarized by *mean (standard deviation)* and compared with one-way ANOVA with predefined contrasts (a). Continuous variables of non-normal distribution (*MMSE* and *GDS*) and the ordinal variable (*education level*) are described by *median (interquartile range)* and compared with Mann-Whitney U tests (b). Binary variables (*sex*, *APOE* ϵ 4 positivity, *APOE* ϵ 4 allele frequency, *APOE* allele distribution and CSF pA β positivity) are described with observed numbers and percentages and compared with Pearson's Chi square tests (c) or Fisher's exact tests when expected count is less than 5 (d).

Table 2

Demographic characteristics, distribution of cognitive stage (SCD, MCI) for symptomatic subject groups, *APOE* alleles and CSF A β pathology of the control and symptomatic subjects classified by recruitment method

	Control subjects			Subjects with cognitive symptoms			
	Without family history	With family history	Abnormal cognitive screening	Recruited as control subjects	Self-referral	Memory clinic referral	Self-versus memory clinic referral
Age at inclusion (SD)	63.2 (9.6) <i>n</i> = 46	58.9 (8.9) <i>n</i> = 86 <i>p</i> < 0.05^a	65.2 (7.6) <i>n</i> = 32 <i>p</i> = n.s. ^a	66.6 (6.5) <i>n</i> = 11 <i>p</i> = n.s. ^a	64.4 (9.7) <i>n</i> = 179 <i>p</i> = n.s. ^a	61.5 (9.1) <i>n</i> = 86 <i>p</i> = n.s. ^a	<i>p</i> < 0.05^a
Female/Total	22/46 47.8 %	53/86 61.6 % <i>p</i> = n.s. ^c	21/32 65.6 % <i>p</i> = n.s. ^c	5/11 45.5 % <i>p</i> = n.s. ^c	97/180 53.9 % <i>p</i> = n.s. ^c	46/87 52.9 % <i>p</i> = n.s. ^c	<i>p</i> = n.s. ^c
Education level (IQR)	3.0 (2.0) <i>n</i> = 46	3.0 (2.0) <i>n</i> = 85 <i>p</i> = 0.05^b	2.0 (2.0) <i>n</i> = 31 <i>p</i> = n.s. ^b	2.0 (2.0) <i>n</i> = 11 <i>p</i> = n.s. ^b	3.0 (2.0) <i>n</i> = 179 <i>p</i> = n.s. ^b	2.5 (2.0) <i>n</i> = 86 <i>p</i> = n.s. ^b	<i>p</i> < 0.01^b
MMSE (IQR)	29.0 (1.0) <i>n</i> = 45	30.0 (1.0) <i>n</i> = 86 <i>p</i> = n.s. ^b	28.0 (2.0) <i>n</i> = 32 <i>p</i> < 0.001^b	27.5 (2.0) <i>n</i> = 10 <i>p</i> < 0.001^b	29.0 (2.0) <i>n</i> = 179 <i>p</i> < 0.05^b	29.0 (3.0) <i>n</i> = 86 <i>p</i> < 0.001^b	<i>p</i> < 0.05^b
SCD	–	–	–	3/11 27.3 %	110/180 61.1 %	41/87 47.1 %	<i>p</i> < 0.05^c
MCI	–	–	–	8/11 72.7 %	70/180 38.9 %	46/87 52.9 %	<i>p</i> < 0.05^c
<i>APOE</i> ϵ 4 positive	9/43 20.9 %	45/82 54.9 % <i>p</i> < 0.001^c	12/32 37.5 % <i>p</i> = n.s. ^c	2/11 18.2 % <i>p</i> = n.s. ^d	71/160 44.4 % <i>p</i> < 0.01^c	50/79 63.3 % <i>p</i> < 0.001^c	<i>p</i> < 0.01^c
<i>APOE</i> ϵ 4 allele frequency	10.5 %	28.7 % <i>p</i> < 0.01^c	20.3 % <i>p</i> = n.s. ^c	9.1 % <i>p</i> = n.s. ^d	25.0 % <i>p</i> < 0.05^c	38.0 % <i>p</i> < 0.001^c	<i>p</i> < 0.01^c
CSF A β ₄₂ positive	2/39 5.1 %	4/62 6.5 % <i>p</i> = n.s. ^d	6/25 24.0 % <i>p</i> < 0.05^d	1/11 9.1 % <i>p</i> = n.s. ^d	37/155 23.9 % <i>p</i> < 0.01^c	29/79 36.7 % <i>p</i> < 0.001^c	<i>p</i> < 0.05^c

The continuous variable of assumed normal distribution (*age at inclusion*) is summarized by *mean (standard deviation)* and compared with one-way ANOVA with predefined contrasts (a). The continuous variable of non-normal distribution (*MMSE*) and the ordinal variable (*education level*) are described by *median (interquartile range)* and compared with Mann-Whitney U tests (b). Binary variables (*sex*, *APOE* ϵ 4 *positivity*, *APOE* ϵ 4 *allele frequency*, and *CSF pA β positivity*) are described with observed numbers and percentages and compared with Pearson's Chi square tests (c) or Fisher's exact tests when expected count is less than 5 (d).

(sensitivity = 0.93, specificity = 0.93, AUC = 0.985; final results are due for publication in Kalheim et al., in submission).

For continuous variables with assumed normal distribution (*age at inclusion*, *CERAD word list recall T-score*, *VOSP silhouettes T-score*, *TMT-B T-score*, and *COWAT T-score*) means for the different groups were compared with one-way ANOVA (analysis of variance) with pre-defined contrasts. Normality was assessed by visual inspection of frequency distributions, Q-Q-plots, and box-plots. Equal variance was assumed for all except *CERAD word list delayed recall*, *VOSP silhouettes*, and *COWAT T-score*, given by Levene's test. Continuous variables of non-normal distribution (*MMSE* and *GDS*) were compared with Mann-Whitney U tests, and *education level* was also tested with Mann-Whitney U, being an ordinal variable. The binary variables (*sex*, *APOE* ϵ 4 *positivity*, *APOE* ϵ 4 *allele frequency*, *APOE* *allele distribution*, and *CSF pA β positivity*) were compared with Pearson's Chi square test or Fisher's exact test when

expected counts were less than 5. All analyses were performed in the Statistical Package for Social Sciences version 24 (Chicago, IL, USA).

RESULTS

Of 577 cases considered, 87 withdrew before finishing the assessment program or did not fulfill the inclusion criteria (see Fig. 1). Of the 490 cases included, 465 were staged at the time of analysis. 46 were normal controls without (NC, age 63.2, SD 9.6) and 86 with first degree relative with dementia (NCFD, age 58.9, SD 8.9), 32 subjects were controls with abnormal cognitive screening (ACS, age 65.2, SD 7.6), 164 were SCD (age 62.3, SD 8.9), and 137 were MCI (age 65.4 SD, 9.8). Further characteristics are shown in Table 1.

Out of 411 cases with available CSF A β ₄₂ values, 96 had increased fractions of pA β (23.4%). 5.1% of the normal control, 6.5% of controls with first-degree relatives, and 16.6% of the SCD cases were




Fig. 1. Initially 577 subjects were considered for inclusion, whereof 87 did not fulfill inclusion criteria or withdrew before finishing the assessment program. 465 subjects were staged, as either normal controls (NC), normal controls with first degree relative (NCFD), controls with abnormal cognitive screening results (ACS), subjective cognitive decline (SCD) or mild cognitive impairment (MCI). At the time of analysis, *APOE* genotyping was available for 445 subjects, whereof 202 were *APOE* $\epsilon 4$ positive. Cerebrospinal fluid data was available for 411 subjects, whereof 96 subjects had pathological levels of $A\beta_{42}$.

pA β , compared to 43.3% of MCI cases ($p < 0.001$ MCI versus NC, Table 2). Out of 445 cases with available *APOE* $\epsilon 4$ status, 243 were negative and 202 were positive. In the NC group, 20.9% were *APOE* $\epsilon 4$ allele positive (close to population normal), whereas in the NCFD, ACS, SCD, and MCI group 54.9% ($p < 0.001$), 37.5% ($p = n.s.$), 43.5% ($p < 0.01$), and 52.4% ($p < 0.001$) were *APOE* $\epsilon 4$ allele positive, respectively when compared to the NC group.

When the symptom subjects were stratified based on family history of dementia, there were 74 SCD subjects without and 90 SCD subjects with family history and 95 MCI subjects without and 42 MCI subjects with family history. There were no significant differences in age, gender, cognitive test results, *APOE* positivity, or CSF $A\beta_{42}$ positivity when SCD subjects with and without family history or MCI subjects with and without family history were compared (data not shown).

In the cognitive symptom group (SCD+MCI) 23.9% of self-referred cases had pA β , compared to 36.7% in the group referred from memory clinics, which is significantly higher fractions than the NC group ($p < 0.01$ and $p < 0.001$, respectively). Similarly, in this self-referred group 44.4% were *APOE* $\epsilon 4$ allele positive and 63.3% of those referred to memory clinics, which is significantly more than in the NC group ($p < 0.01$ and $p < 0.001$, respectively) (Table 2).

Comparing the two recruitment sources, there was a significantly higher percentage of CSF pA β and *APOE* $\epsilon 4$ allele carriers in the group referred to memory clinic compared to self-referred subjects ($p < 0.05$ and $p < 0.01$, respectively). There were also significant differences in age ($p < 0.05$), education level ($p < 0.01$), MMSE ($p < 0.05$), and fractions of SCD and MCI ($p < 0.05$) between these two groups.

DISCUSSION

The DDI project examines incipient disease activity and AD risk factors in pre-dementia and presumptive pre-disease patient and control cohorts. Here, we compared our recruitment strategies to find optimal cohorts consisting of pre-disease at-risk cases and pre-dementia cases with signs of amyloid deposition (Table 2). Compared to NC, we found increased pA β frequencies in both the self-referred and memory clinic-referred groups. Age did not differ significantly between these groups, and relevant patient concern connected to underlying pathology may have been a factor driving recruitment also in the self-referred group.

As expected, frequencies of pA β differed significantly between the control groups and SCD cases compared to MCI cases. Furthermore, while self- and memory clinic-referrals frequently had pA β , the group referred to memory clinics had clearly higher proportions than the self-referral group and are preferred as a source for secondary prevention treatment trials. Controls with first-degree relatives with dementia did not have an increased fraction of pA β , but harbored an increased frequency of risk *APOE* ϵ 4 alleles compared to controls without. Self-referred cases were also at-risk, enriched for *APOE* ϵ 4 alleles, and pA β negative. Thus, the majority among of SCD cases, self-referred cases and NCFD are suitable for primary intervention.

These differences in pA β fractions were not mirrored in *APOE* ϵ 4 allele frequencies. Both the self-referred group and the group referred to memory clinics had significantly higher frequencies, as had the control group with first-degree relatives with dementia indicating that all these groups are at increased risk for AD dementia. Though MCI cases had significantly lower MMSE-scores (and a higher age), *APOE* ϵ 4 allele frequencies were not significantly different compared to SCD and first degree-relative control cases (data not shown). *APOE* ϵ 4 allele frequency was higher in our control groups overall than expected from published Norwegian population frequencies established from healthy blood donors (22.0% compared to 19.8% allele frequency). The NC group (without first degree relatives with dementia) had a lower *APOE* ϵ 4 allele frequency than previously published for an equivalent control group (10.5% versus 14.3%), but close to the frequency in our orthopedic-surgery control cases (11.5%), suggesting that this level may be realistic for the present population [35, 36].

To some extent, inclusion strategies and selection of cutoff levels will always cause bias. The present CSF A β ₄₂ cutoff gives the best fit to flutemetamol PET in (Kalheim et al., in submission). Highly standardized pre-analytical procedures and laboratory handling procedures may have contributed to numerically high values. Clinical follow-up is necessary for ultimate evaluation of CSF A β cutoff levels with the highest predictive power for dementia. Herein, and for other research purposes (inclusion of patients for longitudinal studies or for secondary intervention), a relatively high cutoff allowing for sensitive inclusion of patients at risk (few false negatives) may be beneficial, whereas for clinical purposes fewer false positives may be optimal.

One limitation of this study is the specific mention of first-degree relatives in the advertisements. As such, the present control group has a larger proportion of subjects with first-degree relatives with dementia. Because of this, we have split the control group and this has enabled us to specifically examine first-degree relatives.

In summary, symptomatic cases, both self- and memory clinic-referrals, harbor an increased proportion of cases with incipient AD pathology compared to the normal control group without first-degree relatives with dementia. Controls with first-degree relatives with dementia do not have an increased fraction of pA β , but harbor an increased frequency of risk *APOE* ϵ 4 alleles. There were significantly higher fractions of subjects with pA β , *APOE* ϵ 4 allele carriers and MCI subjects in the group referred from memory clinic compared to self-referred subjects.

Whereas memory clinic referrals are most enriched for cases amenable for secondary intervention studies, self-referred cases are enriched for at-risk, pA β negative cases, putatively suitable for primary intervention.

ACKNOWLEDGMENTS

The project was funded by Norwegian Research Council, NASATS (Dementia Disease Initiation) and the JPND (APGeM) and funding from the regional health authority (Helse Sør-Øst).

We thank Claus Albrechtsen, Elisabeth Gundersen, Mari Thoresen Løkholm, Line Sæther, Erna Utne, Marianne Wettergreen, Berglind Gísladóttir, Marit Knapstad, Reidun Meling, and Synnøve Bremer Skarpenes for clinical examinations and essential help with the project.

Authors' disclosures available online (<http://j-alz.com/manuscript-disclosures/17-0231r1>).

REFERENCES

- [1] Eckerstrom M, Berg AI, Nordlund A, Rolstad S, Sacuiu S, Wallin A (2016) High prevalence of stress and low prevalence of Alzheimer disease CSF biomarkers in a clinical sample with subjective cognitive impairment. *Dement Geriatr Cogn Disord* **42**, 93-105.
- [2] Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Arch Gen Psychiatry* **69**, 98-106.
- [3] Sperling R, Mormino E, Johnson K (2014) The evolution of preclinical Alzheimer's disease: Implications for prevention trials. *Neuron* **84**, 608-622.
- [4] Begum A, Morgan C, Chiu CC, Tylee A, Stewart R (2012) Subjective memory impairment in older adults: Aetiology, salience and help seeking. *Int J Geriatr Psychiatry* **27**, 612-620.
- [5] Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, Mielke MM, Molinuevo JL, Mosconi L, Osorio RS, Perrotin A, Petersen RC, Rabin LA, Rami L, Reisberg B, Rentz DM, Sachdev PS, de la Sayette V, Saykin AJ, Scheltens P, Shulman MB, Slavin MJ, Sperling RA, Stewart R, Uspenskaya O, Vellas B, Visser PJ, Wagner M, Subjective Cognitive Decline Initiative Working Group (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement* **10**, 844-852.
- [6] Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment—beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. *J Intern Med* **256**, 240-246.
- [7] Jansen WJ, Ossenkuppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Amyloid Biomarker Study G, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Forster S, Fortea J, Fosskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabrielewicz T, Gill KD, Gkatzima O, Gomez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Kohler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleo A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonca A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Mollergard HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parretti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodriguez-Rodriguez E, Roe CM, Rot U, Rowe CC, Ruther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schroder J, Schutte C, Seo SW, Soetewey F, Soinen H, Spuru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin AK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. *JAMA* **313**, 1924-1938.
- [8] Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2009) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann Neurol* **67**, 122-131.
- [9] Grambaite R, Reinvang I, Selnes P, Fjell AM, Walhovd KB, Stenset V, Fladby T (2011) Pre-dementia memory impairment is associated with white matter tract affection. *J Int Neuropsychol Soc* **17**, 143-153.
- [10] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers and Lifestyle Research Group (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. *Lancet Neurol* **12**, 357-367.
- [11] Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends Pharmacol Sci* **12**, 383-388.
- [12] Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM (2016) Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. *Curr Opin Neurobiol* **36**, 74-81.
- [13] Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Björnsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature* **488**, 96-99.
- [14] Karch CM, Goate AM (2015) Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol Psychiatry* **77**, 43-51.
- [15] Zhu JB, Tan CC, Tan L, Yu JT (2017) State of play in Alzheimer's disease genetics. *J Alzheimers Dis* **58**, 631-659.
- [16] Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YS, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang LS, Kauwe JS, Huentelman MJ, Myers AJ, Bird TD, Boeve BF, Baldwin CT, Jarvik GP, Crane PK, Rogava E, Barmada MM, Demirci FY, Cruchaga C, Kramer PL, Ertekin-Taner N, Hardy J, Graff-Radford NR, Green RC, Larson EB, St George-Hyslop PH, Buxbaum JD, Evans DA, Schneider JA, Lunetta KL, Kamboh MI, Saykin AJ, Reiman EM, De Jager PL, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Martin ER, Haines JL, Mayeux RP, Farrer LA, Schellenberg GD, Pericak-Vance MA, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barnes LL, Beach TG, Becker JT, Beekly D, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carney RM, Carrasquillo MM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Dick M, Dickson DW, Duara R, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti

- B, Gilbert JR, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lin CF, Lopez OL, Lyketsos CG, Mack WJ, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Murrell JR, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Valadares O, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L (2014) Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study. *JAMA Neurol* **71**, 1394-1404.
- [17] Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P (2015) Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. *Alzheimers Dement Trans Res Clin Interv* **1**, 111-121.
- [18] Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. *Nature* **537**, 50-56.
- [19] Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Frapp J, Tochon-Danguy H, Morandau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szeoke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. *Neurobiol Aging* **31**, 1275-1283.
- [20] Randall C, Mosconi L, de Leon M, Glodzik L (2013) Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. *Front Biosci (Landmark Ed)* **18**, 1150-1173.
- [21] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 270-279.
- [22] Mitchell AJ, Bird V, Rizzo M, Meader N (2010) Diagnostic validity and added value of the Geriatric Depression Scale for depression in primary care: A meta-analysis of GDS30 and GDS15. *J Affect Disord* **125**, 10-17.
- [23] Heaton RK (2004) *Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults: Professional Manual*, Psychological Assessment Resources.
- [24] Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189-198.
- [25] Shulman KI (2000) Clock-drawing: Is it the ideal cognitive screening test? *Int J Geriatr Psychiatry* **15**, 548-561.
- [26] Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, Tariot PN, Silverman JM, Clark CM, Welsh-Bohmer KA, Heyman A (2008) Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years. *Alzheimers Dement* **4**, 96-109.
- [27] Benton AL, Hamsher KD (1989) *Multilingual Aphasia Examination*. AJA Associates, Iowa City.
- [28] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 263-269.
- [29] Warrington EK, James M (1991) *The Visual Object and Space Perception Battery*, Thames Valley Test Company, Bury St Edmunds, England.
- [30] Reitan RM, Wolfson D (1985) *The Halstead-Reitan Neuropsychological Test Battery*, Neuropsychology Press, Tucson.
- [31] Sotaniemi M, Pulliainen V, Hokkanen L, Pirttila T, Hallikainen I, Soininen H, Hanninen T (2012) CERAD-neuropsychological battery in screening mild Alzheimer's disease. *Acta Neurol Scand* **125**, 16-23.
- [32] Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. *Br J Psychiatry* **140**, 566-572.
- [33] Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. *J Intern Med* **256**, 183-194.
- [34] Almdahl IS, Lauridsen C, Selnes P, Kalheim LF, Coello C, Gajdzik B, Moller I, Wettergreen M, Grambaite R, Bjornerud A, Brathen G, Sando SB, White LR, Fladby T (2017) Cerebrospinal fluid levels of amyloid beta 1-43 mirror 1-42 in relation to imaging biomarkers of Alzheimer's disease. *Front Aging Neurosci* **9**, 9.
- [35] Kumar T, Liestol K, Maehlen J, Hiorth A, Jettstuen E, Lind H, Brorson SH (2002) Allele frequencies of apolipoprotein E gene polymorphisms in the protein coding region and promoter region (-491A/T) in a healthy Norwegian population. *Hum Biol* **74**, 137-142.
- [36] Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I, White LR, Lydersen S, Aasly JO (2008) APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. *BMC Neurol* **8**, 9.